|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXO44 |
Gene summary for FBXO44 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXO44 | Gene ID | 93611 |
| Gene name | F-box protein 44 | |
| Gene Alias | FBG3 | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024R4F9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 93611 | FBXO44 | LZE8T | Human | Esophagus | ESCC | 4.52e-02 | 1.12e-01 | 0.067 |
| 93611 | FBXO44 | LZE22T | Human | Esophagus | ESCC | 4.86e-02 | 2.42e-01 | 0.068 |
| 93611 | FBXO44 | LZE24T | Human | Esophagus | ESCC | 1.32e-13 | 2.13e-01 | 0.0596 |
| 93611 | FBXO44 | LZE6T | Human | Esophagus | ESCC | 4.07e-07 | 1.69e-01 | 0.0845 |
| 93611 | FBXO44 | P2T-E | Human | Esophagus | ESCC | 8.44e-26 | 2.54e-01 | 0.1177 |
| 93611 | FBXO44 | P4T-E | Human | Esophagus | ESCC | 1.01e-11 | 2.01e-01 | 0.1323 |
| 93611 | FBXO44 | P5T-E | Human | Esophagus | ESCC | 2.00e-08 | 1.40e-01 | 0.1327 |
| 93611 | FBXO44 | P8T-E | Human | Esophagus | ESCC | 4.28e-11 | 1.60e-01 | 0.0889 |
| 93611 | FBXO44 | P9T-E | Human | Esophagus | ESCC | 4.61e-03 | 5.57e-02 | 0.1131 |
| 93611 | FBXO44 | P10T-E | Human | Esophagus | ESCC | 4.55e-16 | 3.48e-01 | 0.116 |
| 93611 | FBXO44 | P11T-E | Human | Esophagus | ESCC | 9.49e-06 | 3.62e-01 | 0.1426 |
| 93611 | FBXO44 | P12T-E | Human | Esophagus | ESCC | 3.98e-16 | 2.39e-01 | 0.1122 |
| 93611 | FBXO44 | P15T-E | Human | Esophagus | ESCC | 3.25e-15 | 3.05e-01 | 0.1149 |
| 93611 | FBXO44 | P16T-E | Human | Esophagus | ESCC | 1.90e-22 | 3.82e-01 | 0.1153 |
| 93611 | FBXO44 | P17T-E | Human | Esophagus | ESCC | 4.11e-03 | 1.88e-01 | 0.1278 |
| 93611 | FBXO44 | P20T-E | Human | Esophagus | ESCC | 2.57e-22 | 4.12e-01 | 0.1124 |
| 93611 | FBXO44 | P21T-E | Human | Esophagus | ESCC | 5.64e-24 | 4.54e-01 | 0.1617 |
| 93611 | FBXO44 | P22T-E | Human | Esophagus | ESCC | 3.08e-21 | 3.62e-01 | 0.1236 |
| 93611 | FBXO44 | P23T-E | Human | Esophagus | ESCC | 3.70e-10 | 9.00e-02 | 0.108 |
| 93611 | FBXO44 | P24T-E | Human | Esophagus | ESCC | 2.65e-11 | 1.79e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:003650315 | Esophagus | ESCC | ERAD pathway | 82/8552 | 107/18723 | 5.80e-11 | 1.84e-09 | 82 |
| GO:003043314 | Esophagus | ESCC | ubiquitin-dependent ERAD pathway | 66/8552 | 85/18723 | 1.64e-09 | 3.78e-08 | 66 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:19011362 | Esophagus | ESCC | carbohydrate derivative catabolic process | 99/8552 | 172/18723 | 1.11e-03 | 5.54e-03 | 99 |
| GO:00311461 | Esophagus | ESCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
| GO:0006516 | Esophagus | ESCC | glycoprotein catabolic process | 19/8552 | 28/18723 | 1.49e-02 | 4.84e-02 | 19 |
| GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
| GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
| GO:003497620 | Oral cavity | OSCC | response to endoplasmic reticulum stress | 178/7305 | 256/18723 | 2.59e-23 | 6.06e-21 | 178 |
| GO:00304334 | Oral cavity | OSCC | ubiquitin-dependent ERAD pathway | 65/7305 | 85/18723 | 2.12e-12 | 8.99e-11 | 65 |
| GO:00365035 | Oral cavity | OSCC | ERAD pathway | 76/7305 | 107/18723 | 1.76e-11 | 6.11e-10 | 76 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:19011361 | Oral cavity | OSCC | carbohydrate derivative catabolic process | 89/7305 | 172/18723 | 4.52e-04 | 2.73e-03 | 89 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXO44 | SNV | Missense_Mutation | rs752367811 | c.655N>T | p.Arg219Trp | p.R219W | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| FBXO44 | SNV | Missense_Mutation | rs755895637 | c.28N>T | p.Pro10Ser | p.P10S | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FBXO44 | SNV | Missense_Mutation | c.54C>A | p.Phe18Leu | p.F18L | protein_coding | tolerated(0.43) | possibly_damaging(0.615) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| FBXO44 | SNV | Missense_Mutation | novel | c.199N>C | p.Asp67His | p.D67H | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-D1-A3JP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FBXO44 | SNV | Missense_Mutation | novel | c.766N>T | p.Pro256Ser | p.P256S | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FBXO44 | SNV | Missense_Mutation | novel | c.389G>A | p.Gly130Glu | p.G130E | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.879) | TCGA-RC-A6M4-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| FBXO44 | SNV | Missense_Mutation | rs758291610 | c.708N>T | p.Gln236His | p.Q236H | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.456) | TCGA-55-A493-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FBXO44 | SNV | Missense_Mutation | novel | c.716A>G | p.His239Arg | p.H239R | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.503) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FBXO44 | SNV | Missense_Mutation | c.712N>T | p.His238Tyr | p.H238Y | protein_coding | deleterious_low_confidence(0) | benign(0.127) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| FBXO44 | SNV | Missense_Mutation | novel | c.389G>A | p.Gly130Glu | p.G130E | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.879) | TCGA-CV-5434-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |